Wolf Prize

Harvey J. Berger, M.D. Joins Kojin Therapeutics as Chairman, President, and Chief Executive Officer

Retrieved on: 
Wednesday, January 3, 2024
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Ferroptosis, Immunology, Cameron Boyce, Broad Institute, Drug discovery, Autoimmune disease, Science, Virology, Janssen Pharmaceuticals, Research, Chemical biology, MIT, Dana–Farber Cancer Institute, Apoptosis, Conditional sentence, Yale School of Medicine, Bayer, Yang, Therapy, Cancer, Investment, Polaris Partners, ARIAD Pharmaceuticals, Medicine, Harvard University, Yale New Haven Hospital, Scripps Research, Patient, Cardiovascular disease, Colgate University, Harvard Medical School, Organization, Yale school, Wolf Prize, Pharmaceutical industry

Kojin Therapeutics, Inc., a pioneer in cell-state and ferroptosis biology and cutting-edge drug discovery, today announced the appointment of Harvey J. Berger, M.D.

Key Points: 
  • Kojin Therapeutics, Inc., a pioneer in cell-state and ferroptosis biology and cutting-edge drug discovery, today announced the appointment of Harvey J. Berger, M.D.
  • as its new chairman, president, and chief executive officer.
  • He founded ARIAD Pharmaceuticals and led the company from a start-up to a fully integrated global oncology company.
  • Kojin co-founder Professor Stuart Schreiber stated, “We are thrilled to welcome Dr. Berger, a long-time colleague and collaborator, as Kojin’s new chief executive.

The 6th WLA Forum Ends with Strong Call for Global Scientific Cooperation

Retrieved on: 
Thursday, November 9, 2023
Carbon, Mobius, Kavli Institute for Theoretical Physics, WLA, UC, Neuroscience, University of California, Berkeley, Kavli Foundation (United States), Neural computation, Medicine, University of Science and Technology, Max Planck Society, MacArthur Fellows Program, Nobel Prize, Wolf Prize, ARD International Music Competition, Agriculture, Video game, Management, Physiology, Science, Chemistry

At the flagship WLA Life Science Forum, the WLA Intelligent Science Forum, and the WLA Zero Carbon Forum, the world laureates and scholars discussed about the transformation in the fields for applicable solutions to address pressing global issues.

Key Points: 
  • At the flagship WLA Life Science Forum, the WLA Intelligent Science Forum, and the WLA Zero Carbon Forum, the world laureates and scholars discussed about the transformation in the fields for applicable solutions to address pressing global issues.
  • Some really touching and inspiring moments happened during the attention-drawing WLA SHE Forum, which were encouraging for more females to bravely pursuing the scientific ambitions.
  • and Angela Chan Distinguished Chair in Energy and Professor of Chemistry at UC Berkeley emphasized the importance of scientific cooperation to address the global issues.
  • The 7th WLA Forum will take place in 2024 and the nomination for the 2024 WLA Prize will kick off soon.

The 6th WLA Forum Ends with Strong Call for Global Scientific Cooperation

Retrieved on: 
Thursday, November 9, 2023
Carbon, Mobius, Kavli Institute for Theoretical Physics, WLA, UC, Neuroscience, University of California, Berkeley, Multimedia, Kavli Foundation (United States), Neural computation, Medicine, University of Science and Technology, Max Planck Society, MacArthur Fellows Program, Nobel Prize, Wolf Prize, ARD International Music Competition, Agriculture, Video game, Management, Physiology, Science, Chemistry

At the flagship WLA Life Science Forum, the WLA Intelligent Science Forum, and the WLA Zero Carbon Forum, the world laureates and scholars discussed about the transformation in the fields for applicable solutions to address pressing global issues.

Key Points: 
  • At the flagship WLA Life Science Forum, the WLA Intelligent Science Forum, and the WLA Zero Carbon Forum, the world laureates and scholars discussed about the transformation in the fields for applicable solutions to address pressing global issues.
  • Some really touching and inspiring moments happened during the attention-drawing WLA SHE Forum, which were encouraging for more females to bravely pursuing the scientific ambitions.
  • and Angela Chan Distinguished Chair in Energy and Professor of Chemistry at UC Berkeley emphasized the importance of scientific cooperation to address the global issues.
  • The 7th WLA Forum will take place in 2024 and the nomination for the 2024 WLA Prize will kick off soon.

The 6th WLA Forum Will Embark on New Journey in Shanghai

Retrieved on: 
Monday, October 30, 2023
Carbon, Mobius, Destiny, System, Forum, WLA, Education, MRC Laboratory of Molecular Biology, H. Milton Stewart School of Industrial and Systems Engineering, Biochemistry, Turing Award, Operation, ETH, Emeritus, Community of Common Destiny, Professor, Crystallography, Golden Joystick Awards, International Journal of Biological Macromolecules, Research, Multilateralism, Georgia Tech, University of Colorado Boulder, Biology, Student, Europe-Georgia Institute, Molecular biology, University, Nobel Prize, Physics, Wolf Prize, World Cultural Council 30th Award Ceremony, ARD International Music Competition, Video game, Whaling, Management, Science, Chemistry

The Award Ceremony of the 2023 WLA Prize will be held on November 6 at the opening ceremony of the 6th WLA Forum.

Key Points: 
  • The Award Ceremony of the 2023 WLA Prize will be held on November 6 at the opening ceremony of the 6th WLA Forum.
  • Under the annual theme "Science Leads Transformation," the 6th WLA Forum introduces several notable enhancements to its dynamic program – a new chairmanship to the WLA featured forums, such as the WLA Life Science Forum, WLA Intelligent Science Forum, WLA Zero Carbon Forum, WLA Young Scientists Forum, etc.
  • Additionally, a new academic lecture series, the WLA Frontier Lectures, featuring approximately 60 scholarly presentations that showcase cutting-edge research progress will be launched at the 6th WLA Forum.
  • The five laureates of the 2023 WLA Prize announced last month will attend the 6th WLA Forum in person.

Breakthrough RNA-Based Anti-Cancer Immunotherapy Treatments Being Developed by Global Consortium led by the Hadassah Cancer Research Institute

Retrieved on: 
Monday, September 19, 2022
Wolf Prize, Bioinformatics, Therapy, Safety, Molecular biology, Melanoma, MD, RNA transfection, Center, Faculty of Pharmacy, University of Lisbon, University, University of Erlangen–Nuremberg, Hebrew language, HCRI, Biochemistry, Hadassah Medical Center, Immunotherapy, Neoplasm, Cancer, Physician, Cancer epigenetics, Free University of Brussels (1834–1969), Goal, Biocomputing, Acute myeloid leukemia, Uveal melanoma, Centre for Genomic Regulation, Bar-Ilan University, RNA, Research, RNA splicing, Immune system, Pharmaceutical industry, Vaccine, Dietary supplement, Merck, Biobank

JERUSALEM, Sept. 19, 2022 /PRNewswire/ -- The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, announced today that it is leading CancerRNA ( www.cancerna.info ), a global consortium that aims to apply RNA-based therapeutics to successfully unlock anti-cancer immune responses.

Key Points: 
  • JERUSALEM, Sept. 19, 2022 /PRNewswire/ -- The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, announced today that it is leading CancerRNA ( www.cancerna.info ), a global consortium that aims to apply RNA-based therapeutics to successfully unlock anti-cancer immune responses.
  • While RNA-based therapies, namely mRNA vaccines, shined during the pandemic and saved millions of lives, they have yet to be successfully tested in cancer therapies.
  • About the Hadassah Cancer Research Institute:
    Hadassah Cancer Research Institute (HCRI) is a translational research arm of Hadassah Medical Organization and Sharett Cancer Center in Jerusalem.
  • For additional information on the Hadassah Cancer Research Institute and CanceRNA, contact:

Carolyn Bertozzi, Professor and Director of the Sarafan ChEM-H institute at Stanford University, Joins the Rondo Therapeutics Scientific Advisory Board

Retrieved on: 
Wednesday, September 7, 2022
Centre for Protein Engineering, AAAS, German Academy of Sciences at Berlin, University, Research, Tumor microenvironment, American Academy, Therapy, SAN, German National Academy of Sciences Leopoldina, Welch Award in Chemistry, Dickson Prize, Biochemistry, National, Glycosylation, Scientific Advisory Group for Emergencies, American Cancer Society, University of Pittsburgh, National academy, Biology, Immunotherapy, Wolf Prize, Immune system, United States Air Force Scientific Advisory Board, Stanford University, Sarafan, Patient, CMO, Pharmaceutical industry, Medicine, Rondo, Chemistry, Science, Biophysics

SAN FRANCISCO BAY AREA, Calif., Sept. 7, 2022 /PRNewswire/ -- Rondo Therapeutics, a privately-held biotechnology company advancing next-generation immuno-oncology platforms, announces the addition of Carolyn Bertozzi, Ph.D., to its Scientific Advisory Board.

Key Points: 
  • SAN FRANCISCO BAY AREA, Calif., Sept. 7, 2022 /PRNewswire/ -- Rondo Therapeutics, a privately-held biotechnology company advancing next-generation immuno-oncology platforms, announces the addition of Carolyn Bertozzi, Ph.D., to its Scientific Advisory Board.
  • Dr. Bertozzi is a Professor of Chemistry and Director of the Sarafan ChEM-H institute at Stanford Universityand is a world leader in the field of glycobiology, generating new insights regarding disease-associated changes in cell surface glycosylation patterns.
  • Jessica Stark, Ph.D., an American Cancer Society postdoctoral fellow in the Bertozzi Research Group, is also joining Rondo as a scientific consultant.
  • Dr. Stark has pioneered new approaches in understanding the role of glycobiology in the functioning of the innate immune system.

ReviR Therapeutics Announces Addition of Dr. Lynne E. Maquat and Dr. Brian Safina to Scientific Advisory Board

Retrieved on: 
Friday, May 13, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Senior, RNA transfection, American Academy, Immunology, Research, John J. Carty Award for the Advancement of Science, Voyager, Disease, National, University of Rochester, The arts, Wolf Prize, Biochemistry, Warren Alpert Foundation Prize, EJC, NMD, Association, Therapy, RNA Society, National Academy of Medicine, National academy, Biophysics, Patent, Wolf Prize in Medicine, Fellow of the American Association for the Advancement of Science, RNA, Genentech, University, MicroRNA, American Association, United States Air Force Scientific Advisory Board, Harvard Medical School, University of California, San Diego, Entrepreneurship, Neuroscience, Drug discovery, Pharmaceutical industry, Medical device, Medicine, Science, Science

ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced today the formation and members of its Scientific Advisory Board with the appointments of Dr. Lynne E. Maquat and Dr. Brian Safina.

Key Points: 
  • ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced today the formation and members of its Scientific Advisory Board with the appointments of Dr. Lynne E. Maquat and Dr. Brian Safina.
  • We are honored to welcome Dr. Maquat and Dr. Safina to our Scientific Advisory Board, said Peng Yue, Ph.D., Co-Founder, and Chief Executive Officer of ReviR Therapeutics.
  • Each expert will bring in-depth knowledge of RNA biology as well as drug discovery and development expertise.
  • Dr. Maquat brings to ReviR decades of experience in RNA research.

Intra-Cellular Therapies Mourns the Passing of Director, Dr. Richard Lerner

Retrieved on: 
Monday, December 6, 2021
Central nervous system, Rolf Schock Prizes, Princess of Asturias Awards, Medicine, National, Research, GLOBE, Therapy, Wolf Prize, Science, Royal Swedish Academy of Sciences, Family, News, CEO, National academy, MD, Lists of diseases, Scripps Research, CNS, Psychiatry, Wolf Prize in Chemistry, Hispanic Scientist of the Year Award, Nasdaq, Friends, Secondary research, Cell, Pharmaceutical industry

Dr. Lerner served on the board of directors of Intra-Cellular Therapies since the companys formation in 2002.

Key Points: 
  • Dr. Lerner served on the board of directors of Intra-Cellular Therapies since the companys formation in 2002.
  • We are deeply saddened by the news of Richards passing.
  • Richard was an entrepreneurial scientific leader in our field, said Dr.Sharon Mates, Chairman and CEO ofIntra-Cellular Therapies.
  • Intra-Cellular Therapiesis a biopharmaceutical company founded onNobelprize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body.

OPKO Health Announces the Passing of Director Dr. Richard Lerner

Retrieved on: 
Monday, December 6, 2021
Skaggs Institute of Retail Management, Scripps Research, Health, Chemical biology, OPK, Wolf Prize, Industry, Â, Board of directors, Scripps, Leadership, University, Director, Department, Stanford University School of Medicine, Research, GLOBE, Nobel Prize, Rolf Schock Prizes, Board, Hispanic Scientist of the Year Award, Wolf Prize in Chemistry, OPKO Health, Lerner, Biomedical Research, Molecular biology, List of institute professors at the Massachusetts Institute of Technology, Royal Swedish Academy of Sciences, NASDAQ, Management, Pharmaceutical industry

MIAMI, Dec. 06, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces that Director Richard A. Lerner, M.D.

Key Points: 
  • MIAMI, Dec. 06, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces that Director Richard A. Lerner, M.D.
  • Dr. Lerner had served as a Director of OPKO Health since 2007.
  • The Board of Directors and staff of OPKO extend their deepest condolences to the Lerner family and express their gratitude for Dr. Lerners many contributions to OPKO and to the advancement of science.
  • His valuable contributions as a Director over the past 14 years, along with his vast industry experience and passion for science have been integral to the advancement of OPKO Health.

Bioeconomy advocate and UC Berkeley professor David Zilberman named "IICA Chair" for contribution to sustainable development

Retrieved on: 
Monday, November 15, 2021
Carbon, Berkeley, Natural Resources, Biofuel, Institute, Farmer, COVID-19, Ohio, Policy, Sustainability, Wolf Prize, Biology, Food, School, Wolf Prize in Agriculture, Agribusiness, Climate change, Student, SAN, External, Nobel Prize, UC, Research, Ohio State University, Organic, Biotechnology, Program, Sustainable development, IICA, Luis, Center, Knowledge, Income, Multimedia, Rausser College of Natural Resources, Inter-American Institute for Global Change Research, Environment, Pontifical Xavierian University, University of California, Berkeley, University, Distinguishing, Economics, Ig Nobel Prize, São Paulo, University of Buenos Aires, Human, Food security, Renewable energy, Public relations, Agriculture, Forestry

SAN JOSE, Calif., Nov. 15, 2021 /PRNewswire/ -- (IICA) Economist and University of California at Berkeley professor David Zilberman, a leading voice on building the concept of the bioeconomy as a vision for development, was awarded the title of "IICA Chair in Bioeconomy and Sustainable Development".

Key Points: 
  • SAN JOSE, Calif., Nov. 15, 2021 /PRNewswire/ -- (IICA) Economist and University of California at Berkeley professor David Zilberman, a leading voice on building the concept of the bioeconomy as a vision for development, was awarded the title of "IICA Chair in Bioeconomy and Sustainable Development".
  • Zilbermanis a professor in the Agricultural and Resource Economics Department at UC Berkeley.
  • The bioeconomy is a vision that promotes smart industrialization using biological resources, which are converted into value-added products, such as bioproducts, bioenergy and services.
  • "Together, we have developed various activities that have significantly contributed to the development of the bioeconomy in our region.